OpenAI and the FDA Are Holding Talks About Using AI In Drug Evaluation

The FDA is exploring how artificial intelligence can speed up drug approval, with meetings held with OpenAI and Elon Musk's department. FDA Commissioner Marty Makary emphasized the need to modernize drug approval processes using AI, discussing a project called cderGPT aimed at regulating drugs but noting no formal agreements have been made yet. Rafael Rosengarten supports automating certain tasks but stresses the importance of clear guidelines for AI use in healthcare reviews.